Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.

F. A. Holmes, Yasir M. Nagarwala, Virginia Espina, L. A. Liotta, Michael A. Danso, Rosa I. Gallagher, Kristi McIntyre, CK Osborne, JM Mahoney, Allison Florance,

Journal of Clinical Oncology · 2011 · 48 citations · 0 references

Concepts

Abstract

506 Background: Extinction of HER2 signaling in HER2 driven BC may be curative. Alternative activation pathways (HER1, HER3) & mutated downstream signal transducers allow resistance to therapy. Study aim: molecularly characterize HER2+ BC before & after 2 wks anti-HER2 therapy (AHT) with T, L, or T+L & to correlate these with pCR to continuation of same AHT with neoadjuvant chemo (FEC75 x 4 Q3W–>Paclitaxel x 12W). pCR is absence of all invasive cancer in breast & lymph nodes. pCR-Breast used for molecular analysis. Methods: 100 consenting patients (pts) with stage II/III, HER2+ BC, normal cardiac function were randomized to T, L or T+L. Before & after AHT, all pts had core needle biopsies for tissue microarray, stem cell analysis & reverse phase protein microarrays, measuring 60 different phosphoprotein/post-translationally modified protein signaling & gene expression analysis endpoints. Results: pCR in the ITT-E (ITT-E: Pts who had surgery, ≥75% compliant to chemo and took no prohibited meds.) pts: 54%, 45%, 74% for T, L, T+L arms. Analysis by response: 1) Responders (R) have altered HER2 downstream interconnections with PI3K (Spearman rho correlation [rho] 0.5, p=0.12) vs the non-responders [NR] (rho 0.9, p=0.037) & HER3Y1289 correlated (p<0.001 for all endpoints) with EGFRy1173, mTOR 2448, & Beta Catenin 33. 2) NR have a) intact signaling with PI3K (rho 0.9, p=0.037); b) intact interactions with autophagy (PI3K - LC3B rho 0.83, p=0.04); c) intact stem cell – proliferation signaling (Musashi - p70S6 Kinase T389 (p=0.007, rho 0.89), CD44 - PTEN S380 (p<0.001, rho 0.92) were not significant in R. Analysis by AHT, prior to AHT R vs. NR: 1) TRZ MMP-14, 2) LAP EGFRtyr1068 & Fox01/03T24/32 were statistically different. Conclusions: Our study provides a unique in vivo snapshot of molecular changes in signaling pathways of microdissected tumor cells before & after anti-HER2 therapy. Molecular profiles suggest NR use autophagy & stem cell related pathways to evade therapy, while R have disruption of HER2-HER3 linkages & known downstream regulators of growth & transcription. These results provide insights into novel candidate “drugable” targets.